OSUR

Business Context and Reporting Period

Company: OraSure Technologies, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2002
Business Overview: The Company develops, manufactures, and markets oral specimen collection devices, proprietary diagnostic products, and medical devices. Products are sold globally to clinical laboratories, physician offices, hospitals, and government agencies.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenues decreased 6% in the quarter and 3% for the nine-month period compared to 2001. This was driven primarily by a 99% drop in licensing and product development revenue (due to the absence of one-time milestone payments in 2002) and lower international sales of the OraQuick HIV test.
• Margin Compression: Gross margins declined from 67% to 59% (quarterly) and 65% to 60% (nine-month). Management attributed this to lower licensing revenue mix, higher manufacturing preparation costs for OraQuick, and increased scrap rates due to product expiration and demand shifts.
• Expense Management: Research and development expenses decreased 16% (quarterly) and 5% (nine-month) due to lower staffing and consulting costs. However, General and Administrative expenses increased 9% for the nine-month period, largely due to a $0.5 million severance charge for the former CEO.
• Cash Flow: Net cash used in operating activities improved significantly to $(0.79) million for the nine months ended Sep 30, 2002, compared to $(4.26) million in the prior year period, aided by improved accounts receivable collections.

Outlook, Risks, and Unusual Items

• Debt Refinancing: In September 2002, the Company entered a new $10.9 million credit facility with Comerica Bank, refinancing existing debt and lowering the effective interest rate by approximately 300 basis points. The facility includes a $4.0 million revolving working capital line (currently unutilized) and a $3.0 million term loan.
• Covenants: The new credit agreement requires the Company to achieve positive consolidated net income for the fiscal year ending December 31, 2003, and each year thereafter. It also imposes restrictions on dividends, additional indebtedness, and asset sales.
• Strategic Agreements:
  • Abbott Laboratories: Signed an agreement in June 2002 for Abbott to distribute OraQuick in the U.S. The Company expects approximately $4.0 million in product revenues from this arrangement through the end of 2003.
  • bioMerieux: Entered new supply and distribution agreements in October 2002 for the HIV-1 Western Blot test, involving $750,000 in aggregate payments to be amortized through 2005.
• Regulatory Approval: On November 7, 2002 (post-period), the FDA approved the OraQuick test for finger-stick whole blood samples, expanding its authorized use in the U.S.
• Risks: Key risks include reliance on a single customer (28% of Q3 revenue), the ability to meet debt covenants, potential inventory obsolescence, and the success of new product launches.

Investor Verification Checklist

• Debt Covenant Compliance: Verify the Company's ability to achieve positive net income by December 31, 2003, as required by the new Comerica Bank credit facility.
• Inventory Valuation: Assess the adequacy of inventory reserves given the reported increase in scrap rates and product expiration issues.
• Customer Concentration: Monitor the financial health of the largest customer (LabOne, Inc.), which accounted for 28% of Q3 revenues, and the impact of their processing efficiencies on future sales.
• Licensing Revenue Volatility: Confirm the sustainability of revenue streams given the significant drop in non-recurring licensing and development fees compared to the prior year.
• Abbott Distribution Impact: Track the realization of the expected $4.0 million in revenues from the Abbott Laboratories distribution agreement.